Two major studies published in 2026 have converged on a sobering conclusion about women and heart disease in America: the medical system is consistently failing women at two distinct points in their cardiovascular health journey. The first failure occurs during perimenopause, when estrogen and progesterone levels begin their permanent decline and cardiovascular risk rises sharply — a change that is often not addressed because many clinicians, and many women themselves, do not recognize the menopausal transition as a cardiovascular health event. The second failure occurs later, when women who develop advanced heart failure are significantly less likely to be referred for life-saving treatments than men with the same clinical burden.
Together, the data describe a pipeline of missed opportunities that begins in midlife and ends at the threshold of the most aggressive interventions medicine has to offer — with women systematically less likely to access either early prevention or late-stage rescue.
The Perimenopause Warning from the American Heart Association
A study published May 13, 2026 in the Journal of the American Heart Association, using data from the National Health and Nutrition Examination Survey (NHANES), found that perimenopausal women were two times more likely to have a low score on the American Heart Association’s Life’s Essential 8 cardiovascular health metrics compared to women who were still having regular menstrual cycles. The Life’s Essential 8 score assesses blood pressure, blood sugar, cholesterol, weight, smoking status, physical activity, diet quality, and sleep.
Perimenopause, which typically begins in women’s mid-to-late 40s, is characterized by fluctuating estrogen and progesterone levels that directly affect the cardiovascular system. Estrogen has well-documented protective effects on blood vessel function, lipid profiles, and inflammatory pathways. As estrogen levels begin to fall during perimenopause, total cholesterol and LDL cholesterol rise, blood pressure increases, insulin sensitivity decreases, and body fat shifts toward the visceral pattern associated with metabolic risk.
The AHA stated that perimenopause represents a “window of opportunity” for preventive cardiovascular intervention. Women and their clinicians should view the first irregular period — not menopause itself — as a clinical trigger to assess and aggressively manage cardiovascular risk factors.
The Advanced Heart Failure Referral Gap
The second study, presented at the British Cardiovascular Society Annual Conference 2026 and published in Open Heart, analyzed the UK and Ireland National Advanced Heart Failure Audit and found that women accounted for only one-third of referrals for advanced heart failure therapies — heart transplantation and left ventricular assist devices — despite evidence suggesting women carry a comparable burden of advanced heart failure.
“We don’t yet know exactly why this is happening,” said Dr. Owais Dar, consultant cardiologist at Harefield Hospital. “It may involve differences in symptom recognition, help-seeking behavior, clinician decision-making, or a combination of factors. We’re actively researching this now.”
In the United States, a multicenter retrospective analysis of nine advanced heart failure centers found that women accounted for only 26.6 percent of referrals, despite data showing they carry equivalent or higher mortality risk. The American College of Cardiology has explicitly labeled this problem: “Women with Heart Failure: Unheard, Untreated, and Unstudied.”
Advanced heart failure has a prognosis comparable to many cancers — a five-year survival rate of approximately 50 percent without intervention. Heart transplantation and LVAD implantation meaningfully extend survival. Women who are not referred simply do not access those benefits.
Frequently Asked Questions
Q: Why does perimenopause increase cardiovascular risk?
A: Estrogen has protective effects on blood vessel function, lipid profiles, and inflammation. As estrogen declines during perimenopause, total and LDL cholesterol rise, blood pressure increases, insulin sensitivity decreases, and visceral fat accumulation increases.
Q: When should women and their doctors begin discussing cardiovascular risk?
A: The AHA’s 2026 JAHA study recommends that perimenopause be treated as a trigger for comprehensive cardiovascular risk assessment and management, beginning with the first irregular period.
Q: Why are women less likely to be referred for advanced heart failure treatment?
A: Researchers cite differences in symptom presentation, clinician bias in severity assessment, lower self-advocacy, and historical underrepresentation of women in the clinical trials that defined referral criteria.
Q: What are the Life’s Essential 8 cardiovascular health metrics?
A: Blood pressure, blood sugar, cholesterol, body weight, tobacco/nicotine use, physical activity level, diet quality, and sleep health.
